Top Page
Control Bionics Ltd.
(Sydney:CBL)
Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)
Control Bionics Ltd. Business Overview & Revenue Model
Control Bionics Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.14M | 6.14M | 5.35M | 5.64M | 4.50M | 4.09M |
| Gross Profit | 4.11M | 4.11M | 3.90M | 3.71M | -2.91M | 2.50M |
| EBITDA | -5.14M | -5.14M | -5.01M | -5.14M | -5.92M | -3.40M |
| Net Income | -6.11M | -6.11M | -5.91M | -5.63M | -6.11M | -3.55M |
Balance Sheet | ||||||
| Total Assets | 8.23M | 8.23M | 9.03M | 8.70M | 13.44M | 18.35M |
| Cash, Cash Equivalents and Short-Term Investments | 672.66K | 672.66K | 980.76K | 935.50K | 5.21M | 12.33M |
| Total Debt | 435.40K | 435.40K | 961.74K | 128.50K | 284.82K | 14.87K |
| Total Liabilities | 2.72M | 2.72M | 2.76M | 1.58M | 1.51M | 1.19M |
| Stockholders Equity | 5.51M | 5.51M | 6.27M | 7.15M | 11.92M | 17.16M |
Cash Flow | ||||||
| Free Cash Flow | -4.57M | -4.57M | -5.38M | -4.98M | -5.75M | -4.04M |
| Operating Cash Flow | -4.27M | -4.27M | -4.91M | -4.53M | -5.60M | -3.99M |
| Investing Cash Flow | -744.78K | -744.78K | -473.09K | -457.54K | -147.74K | -53.40K |
| Financing Cash Flow | 4.63M | 4.63M | 5.43M | 706.43K | -87.33K | 14.92M |
Control Bionics Ltd. Technical Analysis
Control Bionics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$24.72M | -2.58 | -103.74% | ā | 14.84% | 39.64% | |
48 Neutral | AU$34.03M | -5.45 | -58.27% | ā | -7.20% | 28.70% | |
43 Neutral | AU$49.00M | -8.46 | -513.22% | ā | -34.06% | 75.47% | |
42 Neutral | AU$5.42M | -3.55 | ā | ā | ā | -55.00% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ā | -30.80% | -38.95% | |
37 Underperform | AU$12.36M | -0.64 | -1476.79% | ā | -2.82% | 32.47% |
Control Bionics Ltd. Corporate Events
Control Bionics has signed a two-year US distribution agreement with AAC specialist PRC-Saltillo for its NeuroNode technology, formalising a relationship that has already seen PRC staff trained, devices used in trials and demonstrations, and insurance funding secured for clients. The deal broadens access to NeuroNode’s sEMG-based access method as a complementary option within PRC’s communication portfolio, underpins Control Bionics’ strategy of scaling NeuroNode sales through key regional partners, and is expected to support a gradual but sustainable ramp-up of US revenues following its recent partnership with Tobii Dynavox.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics reported a strategically significant December 2025 quarter highlighted by a $3.8 million capital raise to fund commercial, regulatory and manufacturing initiatives across its core platforms, including NeuroNode and NeuroStrip, in the US and Australian markets. The company advanced its NeuroNode distribution strategy through trials with US organisations and, shortly after the quarter, signed a distribution partnership with Tobii, the global AAC leader, while also becoming one of the first organisations to integrate with Apple’s brain–computer interface protocol, reinforcing its technology leadership and enabling closer alignment with mainstream consumer platforms. Control Bionics completed the acquisition of Neuro Elite Athletics (NeuroBounce), creating a dedicated base for its sports performance program and expansion into elite sport, rehabilitation and broader performance markets, and continued the rollout of NeuroStrip, securing usage agreements with high-profile institutions such as the Australian Institute of Sport, Melbourne Victory, Ohio University, The Mayo Clinic, Mountain Land Physical Therapy and The Burrows Institute, supported by the commencement of scaled manufacturing. Quarterly cash receipts were steady at $1.4 million versus a year earlier, with revenue constrained by industry-wide delays in Australia’s NDIS approvals, but the company indicated underlying demand remains robust and said these strategic moves position it well for execution and growth through 2026.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics has signed an agreement with AAC market leader Tobii Dynavox to run a six‑month pilot in five northwestern U.S. states, under which Tobii Dynavox will evaluate offering Control Bionics’ NeuroNode technology alongside its communication aids, replacing a previous U.S. partner. By integrating NeuroNode’s sEMG-based access with Tobii Dynavox’s eye-gaze systems, the collaboration aims to give users an additional, potentially less fatiguing way to control assistive communication technology and, if successful, could pave the way for a broader U.S. rollout and strengthen Control Bionics’ position in the global AAC ecosystem.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has issued 8,443,747 fully paid ordinary shares on 31 December 2025 without a prospectus or product disclosure statement, relying on provisions of the Corporations Act that allow such an issue to be made to certain investors. The company confirmed it is up to date with its financial reporting and continuous disclosure obligations and stated that there is no undisclosed price-sensitive information, signalling that the new share issue is being conducted within the standard regulatory framework and without additional market-moving information for existing shareholders.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has applied to the ASX for quotation of 8,443,747 new fully paid ordinary shares under the code CBL, with an issue date of 31 December 2025. The move formalises the listing of these previously announced securities, expanding the company’s quoted share base and potentially increasing liquidity for existing investors while signalling ongoing capital markets activity as the business continues to execute its previously disclosed transactions.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has lodged a notice with the ASX for a proposed issue of up to 8,443,747 new fully paid ordinary shares. The securities are to be issued via a placement or other type of issue on 31 December 2025, indicating the company is seeking to raise additional equity capital, which may support its ongoing operations or strategic initiatives and result in dilution for existing shareholders depending on the final pricing and allocation.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics has completed the acquisition of 100% of U.S.-based Neuro Elite Athletics, the company behind the NeuroBounce athletic performance program, via its U.S. subsidiary Control Bionics Ngage Inc., making Neuro Elite Athletics a wholly owned subsidiary. The US$370,028 purchase price was settled entirely in equity through the issuance of 8,443,747 new shares under the company’s existing placement capacity, and management says full ownership will accelerate the integration of NeuroBounce with its NeuroStrip EMG platform, supporting a strategic push into high-growth sports performance, return-to-play and human optimisation markets in the U.S. and Australia while consolidating Neuro Elite’s intellectual property, brand, customers and operations within the group.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Ltd. announced the issuance of 50,000,000 fully paid ordinary shares without disclosure under the Corporations Act. This move indicates the company’s compliance with relevant legal provisions and suggests a strategic effort to enhance its financial position, potentially impacting its market operations and stakeholders.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has announced its U.S. subsidiary’s agreement to acquire the remaining shares of Neuro Elite Athletics, the company behind the NeuroBounce program, for $389,150. This acquisition aims to integrate NeuroBounce with Control Bionics’ NeuroStrip EMG technology, enhancing their presence in high-growth performance markets and accelerating innovation in athletic performance and rehabilitation.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited announced the issuance of nearly two million unquoted equity securities under its 2025 Employee Stock Option Plan. This move is part of an employee incentive scheme, reflecting the company’s commitment to retaining and motivating its workforce, which could enhance its operational efficiency and market competitiveness.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has successfully raised $3.25 million through a private placement of 50 million new shares, priced at $0.065 each. This funding, anchored by Reitham Equity GmbH, will enhance the company’s working capital to accelerate its commercialization programs in assistive technology and emerging neurotechnology markets. The investment is expected to strengthen Control Bionics’ global footprint and support key initiatives in assistive communication, rehabilitation, and sports performance, ultimately improving the quality of life and performance for users worldwide.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Ltd has announced the appointment of Stephen Rix as a director, effective December 1, 2025. Rix holds 100,000 ordinary shares directly and has an indirect interest in 5,634,215 ordinary shares through Windward Capital Pty Limited. This appointment and the associated shareholdings could influence the company’s strategic direction and stakeholder interests.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has appointed Stephen Rix as a Non-Executive Director and the new Chairman of the Board. Rix, who has a strong background in governance and growth across various sectors, has been a long-time investor in Control Bionics, bringing valuable experience as the company aims to scale its technology and expand globally. His appointment is expected to support the company’s mission of delivering life-changing technology and accelerating its expansion into new markets and applications.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has announced the issuance of 8,000,000 unquoted CEO options as part of an employee incentive scheme. This move is likely aimed at aligning the interests of the company’s leadership with its strategic goals, potentially impacting its operational focus and stakeholder engagement.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited announced a change in the director’s interest, with Jeremy Steele acquiring 8 million additional options, increasing his total to over 12 million options. This move, approved at the 2025 AGM, reflects a strategic alignment with the company’s growth objectives and may influence investor confidence and stakeholder engagement.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Ltd. announced the results of its recent meeting of security holders, where several resolutions were passed. Key outcomes include the approval of the remuneration report, the re-election of directors, and the ratification of share issues, reflecting strong shareholder support and positioning the company for future growth.
Control Bionics Limited announced the resignation of its chairman, Dr. Samuel Straface, due to competing commitments. Damian Lismore, an independent director, has been appointed as interim non-executive chairman. This leadership change comes as the company continues to expand its market reach with innovative products like NeuroNode and NeuroStrip, positioning itself for growth in various sectors including health diagnostics and sports performance.
Control Bionics Limited announced a partnership with Apple’s Brain-Computer Interface (BCI) Protocol, marking a significant step in its commercial strategy and future growth. This collaboration is expected to enhance the company’s market positioning and expand its technological capabilities, potentially impacting stakeholders positively by opening new avenues for growth and innovation.
Control Bionics Limited has announced the integration of Apple’s new Brain-Computer Interface (BCI) Human Interface Device protocol into its AAC solutions, enhancing user interaction with Apple devices through neural and motion-based input. This integration simplifies device setup, improves neural feedback, and enables automatic activation of communication tools, thereby strengthening the company’s position in the AAC market and empowering users with disabilities to communicate more effectively.